HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.

Abstract
Olfactomedin 4 (OLFM4) has been demonstrated to serve an important function in tumor progression. This study aims to analyze the correlation between OLFM4 expression and clinicopathological features and the prognostic significance of OLFM4 in the context of smoking status of non-small cell lung cancer (NSCLC) patients. A total of 218 NSCLC patients, who were histopathologically diagnosed from 2001 to 2013, were reviewed in the study. OLFM4 expression was analyzed by immunohistochemical staining of tissue samples. The association of OLFM4 with clinicopathological parameters was evaluated. Overall survival and disease-specific survival were evaluated by Kaplan-Meier survival analysis. Immunohistochemical analyses showed that OLFM4 was highly expressed in 64.2% of NSCLC patients. OLFM4 expression level in NSCLC lesions was strongly correlated with pathologic grade (P = .017), lymph node metastasis (P = .012), peritumor intravascular cancer emboli (P = .03), and smoking status (P < .001). Kaplan-Meier survival curves showed that, among smoking patients, those with low OLFM4 expression had shorter survival time (overall survival and disease-specific survival) than those with high OLFM4 (P < .05). Conclusively, although low OLFM4 expression is not an independent prognostic biomarker, it might indicate worse prognosis for smoking patients with NSCLC, thereby identifying patients who might benefit from targeting OLFM4 therapy.
AuthorsWenmei Su, Liang Luo, Fenping Wu, Zhennan Lai, Xiaofang Li, Zhong Xie, Zhi Tang, Zhixiong Yang, Rong Liang
JournalHuman pathology (Hum Pathol) Vol. 46 Issue 5 Pg. 732-8 (May 2015) ISSN: 1532-8392 [Electronic] United States
PMID25771901 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • OLFM4 protein, human
  • Granulocyte Colony-Stimulating Factor
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Non-Small-Cell Lung (diagnosis, metabolism, pathology)
  • Female
  • Gene Expression Regulation, Neoplastic (genetics)
  • Granulocyte Colony-Stimulating Factor (metabolism)
  • Humans
  • Lung Neoplasms (diagnosis, metabolism, pathology)
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Prognosis
  • Smoking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: